---
document_datetime: 2023-09-21 18:19:45
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/onduarp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: onduarp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7773311
conversion_datetime: 2025-12-27 16:04:25.234482
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Onduarp

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                   | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                          |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| N/0012               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                        | 07/10/2013                                  |                                                | PL                               |                                                                                                                                  |
| PSU/0004             | Periodic Safety Update                                                                                                                                  | 25/04/2013                                  | 13/02/2014                                     | SmPC and PL                      | For further information please refer to: Onduarp-H-2118-Grounds-PSU-04-en.                                                       |
| WS/0362              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Medicinal | 25/04/2013                                  |                                                | SmPC, Annex II, Labelling and PL | For Micardis, Micardis Plus, Kinzalmono, kinzalkomb, Pritor, Pritor Plus Update of sections 4.2, 4.3, 4.4 and 4.5 of the SmPC to |

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                    |                      | authorised   | recommendations in Annex IIIA in bold characters to bring them in line with the printing style on the actual, marketed products. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Micardis and Micardis Plus: (Belgium, Bulgaria and Luxembourg, Estonia, Lithuania) Twynsta/Onduarp (Estonia, Belgium and Luxembourg) Furthermore, the WSA proposed this opportunity to bring the PI in line with the latest QRD template (Version 9).   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0320 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                                                                                                                                                                                  | 15/11/2012         | 15/11/2012 no longer |              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0283 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC in order to include a statement on a drug-drug interaction between amlodipine and simvastatin when used concomitantly. Section 2 of the Package Leaflet is updated accordingly. In addition the MAHhas taken the opportunity to make a correction on the 360 tablets multipack in section 6 of the PIL for Twynsta and Onduarp and in Annex A for Twynsta only. Medicinal | 20/09/2012 product | 24/10/2012           | SmPC and PL  | This type II variation concerns an update of section 4.5 the SmPC to include a new drug-drug interaction between amlodipine and simvastatin. When used concomitantly with amlodipine, the maximum daily dose of simvastatin should not exceed 20 mg.                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |                      |                                             |                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0211   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 05/09/2012 | n/a                  |                                             |                                                                                                                                                                                                                                                                                         |
| WS/0236   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update to section 4.4 of the SmPC to include a warning for diabetic patients when treated with insulin or oral antidiabetics and to include a warning on RAAS blockage in patients with uncontrolled blood pressure. Furthermore the MAH has corrected the visual description of the appearance of the product in section 3 of the SmPC and section 6 of the PL. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 8. Finally the MAH took the opportunity to make some editorial changes in the English Annexes, to make some corrections in the DE, FR, IT, LV, NL and SK Annexes for Onduarp, in the DE, FR, IT, LV, NL and SK Annexes for Twynsta. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data Medicinal product | 19/04/2012 | 25/05/2012 no longer | SmPC, Annex II, Labelling and PL authorised | This type II variation concerns an update of section 4.4 the SmPC to include a warning for diabetic patients when treated with insulin or oral antidiabetics and to include a warning on RAAS blockage in patients with uncontrolled blood pressure, in line with the telmisartan SmPC. |
| WS/0255/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/05/2012 | 24/05/2012           |                                             | Changes to an existing pharmacovigilance system as described in the DDPS. The MAH update the Detailed Description of the Pharmacovigilance System (DDPS) for                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Update of the Description of Pharmacovigilance System (DDPS). C.I.9.z - Changes to an existing pharmacovigilance system as described in the DDPS - Other variation C.I.9.z - Changes to an existing pharmacovigilance system as described in the DDPS - Other variation C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing pharmacovigilance activities C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the   | product no   | longer authorised   | Aptivus, MicardisPlus, Mirapexin, Onduarp, Pradaxa, Sifrol, Trajenta, Twynsta and Viramune.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------|-----------------------------------------------------------------------------------------------|
| IG/0165   | pharmacovigilance system B.III.1.a.1 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/04/2012   | n/a                 |                                                                                               |
| IB/0001/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/02/2012   | n/a                 |                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0002/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure 30/01/2012 Medicinal product no |